Skip to content
Ipsen
-
Ipsen acquires Memo Therapeutics for US$798.4M to secure Potravitug
The acquisition centres on potravitug, a Phase II monoclonal antibody developed to treat BK polyomavirus-associated nephropathy (BKPyVAN).